- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
Bavarian Nordic
Market Cap: DKK 14.3b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 189.50
7D
7.0%
1Y
-20.0%
H. Lundbeck
Market Cap: DKK 41.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 43.86
7D
5.7%
1Y
13.6%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 296.35
7D
-3.5%
1Y
-14.9%
H. Lundbeck
Market Cap: DKK 41.4b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 36.80
7D
3.8%
1Y
13.1%
Gubra
Market Cap: DKK 6.2b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 378.80
7D
0.2%
1Y
6.7%
Strategic Partners
Market Cap: DKK 31.1m
Does not have significant operations.
STRAP
DKK 690.00
7D
-7.4%
1Y
-31.3%